309 related articles for article (PubMed ID: 37190303)
1. The Therapeutic Landscape for
Tria SM; Burge ME; Whitehall VLJ
Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190303
[TBL] [Abstract][Full Text] [Related]
2. Emerging Therapies in Kirsten Rat Sarcoma Virus (+) Non-Small-Cell Lung Cancer.
Karachaliou A; Kotteas E; Fiste O; Syrigos K
Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672529
[TBL] [Abstract][Full Text] [Related]
3. Blockade of mutant RAS oncogenic signaling with a special emphasis on KRAS.
Roskoski R
Pharmacol Res; 2021 Oct; 172():105806. PubMed ID: 34450320
[TBL] [Abstract][Full Text] [Related]
4. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches.
Reck M; Carbone DP; Garassino M; Barlesi F
Ann Oncol; 2021 Sep; 32(9):1101-1110. PubMed ID: 34089836
[TBL] [Abstract][Full Text] [Related]
5. Direct Targeting
Reita D; Pabst L; Pencreach E; Guérin E; Dano L; Rimelen V; Voegeli AC; Vallat L; Mascaux C; Beau-Faller M
Cancers (Basel); 2022 Mar; 14(5):. PubMed ID: 35267628
[TBL] [Abstract][Full Text] [Related]
6. Treatment Strategies for KRAS-Mutated Non-Small-Cell Lung Cancer.
O'Sullivan É; Keogh A; Henderson B; Finn SP; Gray SG; Gately K
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980522
[TBL] [Abstract][Full Text] [Related]
7. Targeting KRAS in Non-Small Cell Lung Cancer.
Corral de la Fuente E; Olmedo Garcia ME; Gomez Rueda A; Lage Y; Garrido P
Front Oncol; 2021; 11():792635. PubMed ID: 35083149
[TBL] [Abstract][Full Text] [Related]
8. Targeting KRAS
Torres-Jiménez J; Espinar JB; de Cabo HB; Berjaga MZ; Esteban-Villarrubia J; Fraile JZ; Paz-Ares L
Drugs; 2024 Apr; ():. PubMed ID: 38625662
[TBL] [Abstract][Full Text] [Related]
9. [Current status and outlook of medical treatment for
Xu W; Zhuo XL; Liu L; Zhao J; Lin XY; Fu GB
Zhonghua Zhong Liu Za Zhi; 2023 Feb; 45(2):111-116. PubMed ID: 36781231
[TBL] [Abstract][Full Text] [Related]
10. Resistance to KRAS
Blaquier JB; Cardona AF; Recondo G
Front Oncol; 2021; 11():787585. PubMed ID: 35004309
[No Abstract] [Full Text] [Related]
11. Targeting
Désage AL; Léonce C; Swalduz A; Ortiz-Cuaran S
Front Oncol; 2022; 12():796832. PubMed ID: 35251972
[TBL] [Abstract][Full Text] [Related]
12. Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes.
Palma G; Khurshid F; Lu K; Woodward B; Husain H
NPJ Precis Oncol; 2021 Nov; 5(1):98. PubMed ID: 34845311
[TBL] [Abstract][Full Text] [Related]
13. Clinical Acquired Resistance to KRAS
Tanaka N; Lin JJ; Li C; Ryan MB; Zhang J; Kiedrowski LA; Michel AG; Syed MU; Fella KA; Sakhi M; Baiev I; Juric D; Gainor JF; Klempner SJ; Lennerz JK; Siravegna G; Bar-Peled L; Hata AN; Heist RS; Corcoran RB
Cancer Discov; 2021 Aug; 11(8):1913-1922. PubMed ID: 33824136
[TBL] [Abstract][Full Text] [Related]
14. Recent progress in targeting KRAS mutant cancers with covalent G12C-specific inhibitors.
Rathod LS; Dabhade PS; Mokale SN
Drug Discov Today; 2023 May; 28(5):103557. PubMed ID: 36934967
[TBL] [Abstract][Full Text] [Related]
15. Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation.
Zheng X; Luo J; Liu W; Ashby CR; Chen ZS; Lin L
Drugs Today (Barc); 2022 Apr; 58(4):175-185. PubMed ID: 35412531
[TBL] [Abstract][Full Text] [Related]
16. Targeting Mutant Kirsten Rat Sarcoma Viral Oncogene Homolog in Non-Small Cell Lung Cancer: Current Difficulties, Integrative Treatments and Future Perspectives.
Li JX; Li RZ; Ma LR; Wang P; Xu DH; Huang J; Li LQ; Tang L; Xie Y; Leung EL; Yan PY
Front Pharmacol; 2022; 13():875330. PubMed ID: 35517800
[TBL] [Abstract][Full Text] [Related]
17. Identification of novel peptide inhibitors for the KRas-G12C variant to prevent oncogenic signaling.
Ajmal A; Ali Y; Khan A; Wadood A; Rehman AU
J Biomol Struct Dyn; 2023; 41(18):8866-8875. PubMed ID: 36300526
[TBL] [Abstract][Full Text] [Related]
18. Molecular Biology and Therapeutic Perspectives for K-Ras Mutant Non-Small Cell Lung Cancers.
Cekani E; Epistolio S; Dazio G; Cefalì M; Wannesson L; Frattini M; Froesch P
Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077640
[TBL] [Abstract][Full Text] [Related]
19. Structural insights into non-hotspot KRAS mutations and their potential as targets for effective cancer therapies.
Ding C; Wang G; Zou W; Mao Y; Ma J
J Biomol Struct Dyn; 2024 Mar; ():1-11. PubMed ID: 38486394
[TBL] [Abstract][Full Text] [Related]
20. KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?
Nagasaka M; Li Y; Sukari A; Ou SI; Al-Hallak MN; Azmi AS
Cancer Treat Rev; 2020 Mar; 84():101974. PubMed ID: 32014824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
